Holen Sie sich die Stockscreener-App
9.375
1.85%
0.185
Schlusskurs vom Vortag:
$9.19
Offen:
$9.24
24-Stunden-Volumen:
763.39K
Relative Volume:
0.24
Marktkapitalisierung:
$1.58B
Einnahmen:
$68.56M
Nettoeinkommen (Verlust:
$-437.99M
KGV:
-2.9631
EPS:
-3.1639
Netto-Cashflow:
$-396.61M
1W Leistung:
+9.73%
1M Leistung:
-9.74%
6M Leistung:
+46.48%
1J Leistung:
+108.00%
1-Tages-Spanne:
$9.16
$9.57
1-Wochen-Bereich:
$8.595
$9.57
52-Wochen-Spanne:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.38 | 1.55B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
436.71 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.47 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.15 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
How Marianne De Backer saved Vir Biotechnology after flu drug failure - The Business Journals
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - AOL.com
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares - AOL.com
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story - Yahoo Finance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - The Motley Fool
Vir Biotechnology’s SWOT analysis: stock gains momentum on partnership and clinical progress - Investing.com UK
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips - Investing.com Nigeria
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver Congress 2026 - marketscreener.com
VIR: Vir Biotechnology Prepares to Present Trial Data at EASL Co - GuruFocus
Vir Biotechnology to present hepatitis delta trial data at EASL By Investing.com - Investing.com South Africa
Vir Biotechnology to present hepatitis delta trial data at EASL - Investing.com UK
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial - TipRanks
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 - Business Wire
Boxer Capital Management Boosts Vir Biotechnology Holdings in Q1 2026 FilingNews and Statistics - IndexBox
User | bigspringherald.comVir Biotechnology, Inc.Common Stock (Nasdaq:VIR) Stock Quote - FinancialContent
Vir Biotechnology, Inc.Common Stock (NQ: VIR - FinancialContent
Vir Biotechnology rated buy on strong cash, late-stage drugs, and key partnerships through 2028 - Pluang
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity (NASDAQ:VIR) - Seeking Alpha
SoftBank group reports 10.95M-share stake in Vir Biotechnology (VIR) - Stock Titan
How Marianne De Backer saved Vir after flu drug failure - The Business Journals
Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Vir Biotech May 2026 slides: CHD combo hits 88% viral suppression - Investing.com
Q2 EPS Estimates for Vir Biotechnology Cut by HC Wainwright - MarketBeat
TradingKey - TradingKey
Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next - simplywall.st
Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - Yahoo Finance
A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress - Yahoo Finance
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors. - Yahoo Finance
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):